 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 December 1993 | Volume 119 Issue 12 | Pages 1168-1174
Objective: To evaluate infectious morbidity associated with long-term use of venous access devices.
Design: Prospective, observational study.
Setting: Comprehensive cancer center at a university hospital.
Participants: 1431 consecutive patients with cancer requiring 1630 venous access devices for long-term use inserted between 1 June 1987 and 31 May 1989.
Measurements: Quantitative microbiologic tests to identify device-related bacteremia and fungemia, catheter tunnel infection, pocket infection in implantable port devices, and site infections; number of days the device remained in situ and time until infectious morbidity; vessel or device thrombosis and device breakage.
Results: At least one device-related infection occurred with 341 of 788 (43% [95% CI, 39% to 47%]) catheters compared with 57 of 680 (8% [CI, 6% to 10%]) completely implanted ports (P
Conclusions: The incidence of infections per device-day was 12 times greater with catheters than with ports. Patients with solid tumors were the least likely to have device-related infectious morbidity compared with those with hematologic cancers. The reasons for the difference in infectious complications is uncertain but may be attributable to type of disease, intensity of therapy, frequency with which devices are accessed, or duration of neutropenia.
Author and Article Information
From the Memorial Sloan-Kettering Cancer Center and Cornell University Medical College, New York, New York.
ARTICLE
Infectious Morbidity Associated with Long-Term Use of Venous Access Devices in Patients with Cancer
0.001). Device-related bacteremia or fungemia is the predominant infection occurring with catheters, whereas ports have a more equal distribution of pocket, site, and device-related bacteremia. The predominant organisms isolated in catheter-related bacteremia were gram-negative bacilli (55%) compared with gram-positive cocci (65.5%) in port-related bacteremia. The number of infections per 1000 device days was 2.77 (95% CI, 2.48 to 3.06) for catheters compared with 0.21 (CI, 0.16 to 0.27) for ports (P 0.001). Based on a parametric model of time to first infection, devices lasted longer in patients with solid tumors than in those with hematopoietic tumors. Ports lasted longer than catheters across all patient groups.
Requests for Reprints: Jeffrey S. Groeger, MD, Special Care Unit, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.
This article has been cited by other articles:
|
|
 |
|
  M. E. Falagas, K. Fragoulis, I. A. Bliziotis, and I. Chatzinikolaou Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials J. Antimicrob. Chemother., March 1, 2007; 59(3): 359 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hanna, R. Benjamin, I. Chatzinikolaou, B. Alakech, D. Richardson, P. Mansfield, T. Dvorak, M. F. Munsell, R. Darouiche, H. Kantarjian, et al. Long-Term Silicone Central Venous Catheters Impregnated With Minocycline and Rifampin Decrease Rates of Catheter-Related Bloodstream Infection in Cancer Patients: A Prospective Randomized Clinical Trial J. Clin. Oncol., August 1, 2004; 22(15): 3163 - 3171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Dillon, G. R. Jones, H. A. Bagnall-Reeb, J. D. Buckley, E. S. Wiener, and G. M. Haase Prophylactic Urokinase in the Management of Long-Term Venous Access Devices in Children: A Children's Oncology Group Study J. Clin. Oncol., July 1, 2004; 22(13): 2718 - 2723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Biffi, S. Pozzi, A. Agazzi, U. Pace, A. Floridi, S. Cenciarelli, V. Peveri, A. Cocquio, B. Andreoni, and G. Martinelli Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients Ann. Onc., February 1, 2004; 15(2): 296 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Verso and G. Agnelli Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients J. Clin. Oncol., October 1, 2003; 21(19): 3665 - 3675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. W. Klerk, S. M. Smorenburg, and H. R. Buller Thrombosis Prophylaxis in Patient Populations With a Central Venous Catheter: A Systematic Review Arch Intern Med, September 8, 2003; 163(16): 1913 - 1921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Seifert, O. Cornely, K. Seggewiss, M. Decker, D. Stefanik, H. Wisplinghoff, and G. Fatkenheuer Bloodstream Infection in Neutropenic Cancer Patients Related to Short-Term Nontunnelled Catheters Determined by Quantitative Blood Cultures, Differential Time to Positivity, and Molecular Epidemiological Typing with Pulsed-Field Gel Electrophoresis J. Clin. Microbiol., January 1, 2003; 41(1): 118 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. O'Grady, M. Alexander, E. P. Dellinger, J. L. Gerberding, S. O. Heard, D. G. Maki, H. Masur, R. D. McCormick, L. A. Mermel, M. L. Pearson, et al. Guidelines for the Prevention of Intravascular Catheter-Related Infections Pediatrics, November 1, 2002; 110(5): e51 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. McNelis, J. Zarcone, and A. Jurkiewicz Outcome of Subcutaneously Implanted Catheters in a Teaching Hospital American Journal of Medical Quality, September 1, 2002; 17(5): 185 - 188. [Abstract] [PDF]
|
|
|
|
|
|
C. Arpin, V. Dubois, A.-M. Rogues, F. Menard, A.-M. Gavinet, J.-P. Maire, J.-P. Gachie, M.-C. Bezian, and C. Quentin Cross-Infection Due to Imipenem-Resistant Bacteroides fragilis Associated with a Totally Implantable Venous Port J. Clin. Microbiol., August 1, 2002; 40(8): 3032 - 3034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Walshe, S. F. Malak, J. Eagan, and K. A. Sepkowitz Complication Rates Among Cancer Patients With Peripherally Inserted Central Catheters J. Clin. Oncol., August 1, 2002; 20(15): 3276 - 3281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Funaki Central Venous Access: A Primer for the Diagnostic Radiologist Am. J. Roentgenol., August 1, 2002; 179(2): 309 - 318. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Marconi, I. Francolini, A. Piozzi, and R. D. Rosa Antibiotic Releasing Urethane Polymers for Prevention of Catheter Related Infections Journal of Bioactive and Compatible Polymers, September 1, 2001; 16(5): 393 - 407. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Haimi-Cohen, N. Husain, J. Meenan, G. Karayalcin, M. Lehrer, and L. G. Rubin Vancomycin and Ceftazidime Bioactivities Persist for at Least 2 Weeks in the Lumen in Ports: Simplifying Treatment of Port-Associated Bloodstream Infections by Using the Antibiotic Lock Technique Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1565 - 1567. [Abstract] [Full Text]
|
|
|
|
|
|
D. Kuizon, S. M. Gordon, and B. L. Dolmatch Single-Lumen Subcutaneous Ports Inserted by Interventional Radiologists in Patients Undergoing Chemotherapy: Incidence of Infection and Outcome of Attempted Catheter Salvage Arch Intern Med, February 12, 2001; 161(3): 406 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. B. Malgrange, M. C. Escande, and S. Theobald Validity of Earlier Positivity of Central Venous Blood Cultures in Comparison with Peripheral Blood Cultures for Diagnosing Catheter-Related Bacteremia in Cancer Patients J. Clin. Microbiol., January 1, 2001; 39(1): 274 - 278. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. R. Donowitz, D. G. Maki, C. J. Crnich, P. G. Pappas, and K. V.I. Rolston Infections in the Neutropenic Patient-- New Views of an Old Problem Hematology, January 1, 2001; 2001(1): 113 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. O. Trerotola Hemodialysis Catheter Placement and Management Radiology, June 1, 2000; 215(3): 651 - 658. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. S. Dhillon and C. Watanakunakorn Pneumococcal Bacteremia Associated With an Infected Central Venous Catheter Chest, May 1, 2000; 117(5): 1515 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Tokars, S. T. Cookson, M. A. McArthur, C. L. Boyer, A. J. McGeer, and W. R. Jarvis Prospective Evaluation of Risk Factors for Bloodstream Infection in Patients Receiving Home Infusion Therapy Ann Intern Med, September 7, 1999; 131(5): 340 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Carratalà, J. Niubó, A. Fernández-Sevilla, E. Juvé, X. Castellsagué, J. Berlanga, J. Liñares, and F. Gudiol Randomized, Double-Blind Trial of an Antibiotic-Lock Technique for Prevention of Gram-Positive Central Venous Catheter-Related Infection in Neutropenic Patients with Cancer Antimicrob. Agents Chemother., September 1, 1999; 43(9): 2200 - 2204. [Abstract] [Full Text]
|
|
|
|
|
|
T. U. Anthony and L. G. Rubin Stability of Antibiotics Used for Antibiotic-Lock Treatment of Infections of Implantable Venous Devices (Ports) Antimicrob. Agents Chemother., August 1, 1999; 43(8): 2074 - 2076. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Krug, D. Psathakis, U. Hirsch, and H.-P. Bruch The K-port concept: Proposal for optimising a fully implantable port system Journal of Oncology Pharmacy Practice, June 1, 1999; 5(2): 67 - 74. [Abstract] [PDF]
|
|
|
|
|
|
E. J. Bow, M. G. Kilpatrick, and J. J. Clinch Totally Implantable Venous Access Ports Systems for Patients Receiving Chemotherapy for Solid Tissue Malignancies: A Randomized Controlled Clinical Trial Examining the Safety, Efficacy, Costs, and Impact on Quality of Life J. Clin. Oncol., April 1, 1999; 17(4): 1267 - 1267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Gilbert, R. J. Dworkin, S. R. Raber, and J. E. Leggett Outpatient Parenteral Antimicrobial-Drug Therapy N. Engl. J. Med., September 18, 1997; 337(12): 829 - 839. [Full Text] [PDF]
|
|
|
|
|
|
W. D. Haire and R. P. Lieberman Defining the Risks of Subclavian-Vein Catheterization N. Engl. J. Med., December 29, 1994; 331(26): 1769 - 1770. [Full Text]
|
|
|
|
 |
|
 INFECTIONS WITH VENOUS ACCESS DEVICES Journal Watch (General), December 31, 1993; 1993(1231): 4 - 4. [Full Text]
|
|
Article
